{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:31:09Z","timestamp":1786692669355,"version":"build-2736575974"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"DOI":"10.1007\/s11596-026-00229-1","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:51:40Z","timestamp":1786686700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nose-to-Brain Nanocarriers for Migraine Management: A Comprehensive Review of Drug Delivery Strategies\u00a0and Translational Challenges"],"prefix":"10.1007","author":[{"given":"Hala","family":"Bashtawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"229_CR1","doi-asserted-by":"crossref","unstructured":"Virmani R, Virmani T, Pathak K. Nanovesicles for delivery of central nervous system drugs. Applications of Nanovesicular Drug Delivery. Amsterdam: Elsevier; 2022:315\u2013339.","DOI":"10.1016\/B978-0-323-91865-7.00004-3"},{"key":"229_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.9734\/jpri\/2021\/v33i34B31853","volume":"33","author":"SV Anusha","year":"2021","unstructured":"Anusha SV, Ratna J, Swarnalatha S, et al. Brain targeting through intranasal route: an overview. J Pharm Res Int. 2021:112\u2013124.","journal-title":"J Pharm Res Int."},{"issue":"5","key":"229_CR3","volume":"13","author":"K Kaur","year":"2021","unstructured":"Kaur K, Hernandez V, Al Hajaj SW, et al. The efficacy of herbal supplements and nutraceuticals for prevention of migraine: can they help? Cureus. 2021;13(5): e14868","journal-title":"Cureus."},{"key":"229_CR4","unstructured":"Assadpour S, Shiran MR, Akhtari J. Chitosan coating of anionic liposomes containing sumatriptan succinate: a candidate for nasal administration. 2021."},{"issue":"1","key":"229_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/adt.2022.088","volume":"21","author":"D Mathure","year":"2023","unstructured":"Mathure D, Sutar AD, Ranpise H, et al. Preparation and optimization of liposome containing ThermosensitiveIn SituNasal hydrogel system for brain delivery of sumatriptan succinate. ASSAY Drug Dev Technol. 2023;21(1):3\u201316.","journal-title":"ASSAY Drug Dev Technol."},{"issue":"5","key":"229_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/md20050335","volume":"20","author":"P Mura","year":"2022","unstructured":"Mura P, Maestrelli F, Cirri M, et al. Multiple roles of chitosan in mucosal drug delivery: an updated review. Mar Drugs. 2022;20(5):335.","journal-title":"Mar Drugs."},{"key":"229_CR7","doi-asserted-by":"publisher","first-page":"rqac003","DOI":"10.1093\/rpsppr\/rqac003","volume":"1","author":"C de Barros","year":"2022","unstructured":"de Barros C, Portugal I, Batain F, et al. Formulation, design and strategies for efficient nanotechnology-based nasal delivery systems. RPS Pharm Pharmacol Rep. 2022;1:rqac003.","journal-title":"RPS Pharm Pharmacol Rep"},{"key":"229_CR8","first-page":"3","volume-title":"Recent trends in nanotechnology for brain delivery: a brief outlook","author":"C Vitorino","year":"2021","unstructured":"Vitorino C, Jorge A, Pais A. Recent trends in nanotechnology for brain delivery: a brief outlook. Nanoparticles for Brain Drug Delivery: Jenny Stanford Publishing; 2021:3\u20137."},{"key":"229_CR9","unstructured":"Schwinghammer TL, DiPiro JT, Ellingrod VL, et al. Pharmacotherapy handbook. McGraw Hill; 2021."},{"key":"229_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/med\/9780190888770.003.0007","volume-title":"Comprehensive review of headache medicine","author":"M Levin","year":"2025","unstructured":"Levin M. International classification of headache disorders and diagnosis of migraine and its subtypes. In: Levin M, editor. Comprehensive review of headache medicine. 2nd ed. Oxford: Oxford University Press; 2025:101\u2013114."},{"issue":"1","key":"229_CR11","first-page":"16","volume":"28","author":"MG Narimani","year":"2025","unstructured":"Narimani MG, Kalalinia F, Marouzi S, et al. Nanoformulation innovations: Revolutionizing precision in migraine therapy. 2025;28(1):16.","journal-title":"Iran J Basic Med Sci."},{"issue":"1","key":"229_CR12","first-page":"90","volume":"13","author":"S Assadpour","year":"2022","unstructured":"Assadpour S, Akhtari J, Shiran MR. Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine. 2022;13(1):90.","journal-title":"Casp J Int Med."},{"issue":"4","key":"229_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molmed.2025.08.009","volume":"32","author":"U Ashraf","year":"2026","unstructured":"Ashraf U, Goadsby PJ. Migraine: advances in treatment. Trends Mol Med. 2026;32(4):385\u2013398.","journal-title":"Trends Mol Med."},{"issue":"7","key":"229_CR14","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, et al. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654\u20133666.","journal-title":"J Neurol."},{"key":"229_CR15","doi-asserted-by":"crossref","unstructured":"Haanes KA, Edvinsson L. Molecular and cellular mechanisms of CGRP antagonists. Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing,; 2022:19\u201331.","DOI":"10.1007\/978-3-030-95334-8_2"},{"key":"229_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.874193","volume":"13","author":"LK Balcziak","year":"2022","unstructured":"Balcziak LK, Russo AF. Dural immune cells, CGRP, and migraine. Front Neurol. 2022;13:874193.","journal-title":"Front Neurol."},{"key":"229_CR17","doi-asserted-by":"crossref","unstructured":"Alexander A, Agrawal M, Bhupal Chougule M, et al. Nose-to-brain drug delivery. Nanopharmaceuticals. Amsterdam: Elsevier; 2020:175\u2013200.","DOI":"10.1016\/B978-0-12-817778-5.00009-9"},{"issue":"15","key":"229_CR18","doi-asserted-by":"publisher","first-page":"12268","DOI":"10.3390\/ijms241512268","volume":"24","author":"M Silvestro","year":"2023","unstructured":"Silvestro M, Iannone LF, Orologio I, et al. Migraine treatment: towards new pharmacological targets. Int J Mol Sci. 2023;24(15):12268.","journal-title":"Int J Mol Sci."},{"key":"229_CR19","doi-asserted-by":"crossref","unstructured":"Rivera-Mancilla E, MaassenVanDenBrink A. Novel pharmacological targets of migraine: an overview. Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing. 2022:1\u201317.","DOI":"10.1007\/978-3-030-95334-8_1"},{"issue":"11","key":"229_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17512433.2024.2417655","volume":"17","author":"M Waliszewska-Pros\u00f3\u0142","year":"2024","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Raffaelli B, Straburzy\u0144ski M, et al. Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. Expert Rev Clin Pharmacol. 2024;17(11):1039\u20131051.","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"22","key":"229_CR21","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/cells12222649","volume":"12","author":"M Tanaka","year":"2023","unstructured":"Tanaka M, Szab\u00f3 \u00c1, K\u00f6rt\u00e9si T, et al. From CGRP to PACAP, VIP, and beyond: unraveling the next chapters in migraine treatment. Cells. 2023;12(22):2649.","journal-title":"Cells."},{"issue":"3","key":"229_CR22","doi-asserted-by":"publisher","first-page":"033310242311521","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023;43(3):03331024231152169.","journal-title":"Cephalalgia."},{"key":"229_CR23","doi-asserted-by":"publisher","first-page":"1708226","DOI":"10.3389\/fphar.2025.1708226","volume":"16","author":"B Jakubowska","year":"2025","unstructured":"Jakubowska B, Sowa-Ku\u0107ma M. Gepants: targeting the CGRP pathway for migraine relief. Front Pharmacol. 2025;16:1708226.","journal-title":"Front Pharmacol."},{"key":"229_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejpb.2021.12.014","volume":"171","author":"A Gebril","year":"2022","unstructured":"Gebril A, Obeid MA, Bennett EM, et al. Mucosal and systemic immune responses following mucosal immunisation of tetanus toxoid entrapped in lipid nanoparticles prepared by microwave reactor. Eur J Pharm Biopharm. 2022;171:11\u201318.","journal-title":"Eur J Pharm Biopharm."},{"issue":"11","key":"229_CR25","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/jcm10112468","volume":"10","author":"V Martin","year":"2021","unstructured":"Martin V, Hoekman J, Aurora SK, et al. Nasal delivery of acute medications for migraine: the upper versus lower nasal space. J Clin Med. 2021;10(11):2468.","journal-title":"J Clin Med."},{"key":"229_CR26","doi-asserted-by":"publisher","first-page":"3692065","DOI":"10.1155\/2022\/3692065","volume":"2022","author":"S Assadpour","year":"2022","unstructured":"Assadpour S, Shiran MR, Asadi P, et al. Harnessing intranasal delivery systems of sumatriptan for the treatment of migraine. BioMed Res Int. 2022;2022:3692065.","journal-title":"BioMed Res Int."},{"issue":"1","key":"229_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s10194-023-01662-6","volume":"24","author":"G Li","year":"2023","unstructured":"Li G, Duan S, Zhu T, et al. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):129.","journal-title":"J Headache Pain."},{"issue":"2","key":"229_CR28","volume":"7","author":"AA Khan","year":"2024","unstructured":"Khan AA, Qayyum SN, Ghaddar SA. Migraine management: assessing the potential of newly FDA-approved Zavzpret nasal spray as first-line therapy. Int J Surg Glob Health. 2024;7(2):e0314.","journal-title":"Int J Surg Glob Health."},{"issue":"9","key":"229_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S. Zavegepant: first approval. Drugs. 2023;83(9):825\u2013831.","journal-title":"Drugs."},{"issue":"6","key":"229_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.18553\/jmcp.2025.31.6.598","volume":"31","author":"H Fan","year":"2025","unstructured":"Fan H, Wadolowski J, Shan R, et al. Clinical evaluation of zavegepant for the acute treatment of migraine. J Manag Care Specialty Pharm. 2025;31(6):598\u2013602.","journal-title":"J Manag Care Specialty Pharm."},{"issue":"1","key":"229_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-025-01984-7","volume":"26","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Tang Y, Li L, et al. The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature. J Headache Pain. 2025;26(1):48.","journal-title":"J Headache Pain."},{"key":"229_CR32","doi-asserted-by":"crossref","unstructured":"Devadoss T, Pingili RB. Drugs under clinical trials for the treatment of migraine. Management of Migraine Pain. Singapore: Springer Nature Singapore 2024:229\u2013249.","DOI":"10.1007\/978-981-97-4529-6_12"},{"key":"229_CR33","unstructured":"Multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of PRT-064040 nasal spray for the acute treatment of migraine [Internet]. Bethesda (MD): National Library of Medicine (US); 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07304518. Identifier: NCT07304518."},{"issue":"10","key":"229_CR34","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.2174\/1386207323666200914110012","volume":"24","author":"AAA Aljabali","year":"2021","unstructured":"Aljabali AAA, Alzoubi L, Hamzat Y, et al. A potential MRI agent and an anticancer drug encapsulated within CPMV virus-like particles. Comb Chem High Throughput Screen. 2021;24(10):1557\u20131571.","journal-title":"Comb Chem High Throughput Screen."},{"issue":"4","key":"229_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"LA Keller","year":"2022","unstructured":"Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735\u2013757.","journal-title":"Drug Deliv Transl Res."},{"key":"229_CR36","volume":"5","author":"G Kaur","year":"2023","unstructured":"Kaur G, Goyal J, Behera PK, et al. Unraveling the role of chitosan for nasal drug delivery systems: a review. Carbohydr Polym Technol Appl. 2023;5:100316.","journal-title":"Carbohydr Polym Technol Appl."},{"key":"229_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.22159\/ijap.2021v13i2.40404","volume":"13","author":"S Chattopadhyay","year":"2021","unstructured":"Chattopadhyay S, Das S, Sarma KN. Nose-to-brain drug delivery: an update to the alternative path to successful targeted anti-migraine drugs. Int J App Pharm. 2021:67\u201375.","journal-title":"Int J App Pharm."},{"key":"229_CR38","volume-title":"Aulton\u2019s pharmaceutics: the design and manufacture of medicines","author":"GP Martin","year":"2021","unstructured":"Martin GP, Lansley AB. Nasal drug delivery. In: Taylor KMG, Aulton ME, editors. Aulton\u2019s pharmaceutics: the design and manufacture of medicines. 6th ed. Amsterdam: Elsevier; 2021.","edition":"6"},{"issue":"1","key":"229_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/pharmaceutics15010207","volume":"15","author":"VA Duong","year":"2023","unstructured":"Duong VA, Nguyen TTL, Maeng HJ. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics. 2023;15(1):207.","journal-title":"Pharmaceutics."},{"key":"229_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2023.100714","volume":"99","author":"S Khute","year":"2023","unstructured":"Khute S, Jangde RK. Optimization of nasal liposome formulation of venlafaxine hydrochloride using a box-behnken experimental design. Curr Ther Res. 2023;99:100714.","journal-title":"Curr Ther Res."},{"key":"229_CR41","first-page":"291","volume-title":"Drug delivery systems","author":"V Pandey","year":"2021","unstructured":"Pandey V, Gadeval A, Asati S, et al. Formulation strategies for nose-to-brain delivery of therapeutic molecules. In: Tekade RK, editor. Drug delivery systems. Amsterdam: Elsevier; 2020:291\u2013332."},{"key":"229_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2022.101631","volume":"29","author":"ML Formica","year":"2022","unstructured":"Formica ML, Real DA, Picchio ML, et al. On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022;29:101631.","journal-title":"Appl Mater Today."},{"issue":"5","key":"229_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/ph18050615","volume":"18","author":"TTL Nguyen","year":"2025","unstructured":"Nguyen TTL, Duong VA. Advancements in nanocarrier systems for nose-to-brain drug delivery. Pharmaceuticals. 2025;18(5):615.","journal-title":"Pharmaceuticals."},{"issue":"6","key":"229_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2174\/2210681209666190807145229","volume":"10","author":"AAA Aljabali","year":"2020","unstructured":"Aljabali AAA, Obeid MA. Inorganic-organic nanomaterials for therapeutics and molecular imaging applications. Nanosci Nanotechnol Asia. 2020;10(6):748\u2013765.","journal-title":"Nanosci Nanotechnol Asia."},{"issue":"46","key":"229_CR45","doi-asserted-by":"publisher","first-page":"29080","DOI":"10.1039\/D1RA06087B","volume":"11","author":"UU Mohd Nordin","year":"2021","unstructured":"Mohd Nordin UU, Ahmad N, Salim N, et al. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Adv. 2021;11(46):29080\u201329101.","journal-title":"RSC Adv."},{"issue":"12","key":"229_CR46","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/pharmaceutics13122049","volume":"13","author":"D Lee","year":"2021","unstructured":"Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021;13(12):2049.","journal-title":"Pharmaceutics."},{"issue":"3","key":"229_CR47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.5530\/ijpi.2020.3.61","volume":"10","author":"RR Padalkar","year":"2020","unstructured":"Padalkar RR, Madgulkar AR, Bhalekar MR. Brain targeted delivery of rizatriptan using glutathione conjugated liposomes through transmucosal nasal route. Int J Pharm Investig. 2020;10(3):344\u2013350.","journal-title":"Int J Pharm Investig."},{"key":"229_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/978-1-0716-1205-7_41","volume-title":"Melanoma","author":"MA Obeid","year":"2021","unstructured":"Obeid MA, Aljabali AAA, Rezigue M, et al. Use of nanoparticles in delivery of nucleic acids for melanoma treatment. In: Hargadon KM, editor. Melanoma. New York, NY: Springer US; 2021:591\u2013620."},{"issue":"3","key":"229_CR49","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/molecules29030636","volume":"29","author":"AM Agiba","year":"2024","unstructured":"Agiba AM, Arreola-Ram\u00edrez JL, Carbajal V, et al. Light-responsive and dual-targeting liposomes: from mechanisms to targeting strategies. Molecules. 2024;29(3):636.","journal-title":"Molecules."},{"issue":"1","key":"229_CR50","first-page":"11","volume":"3","author":"AK Chettupalli","year":"2025","unstructured":"Chettupalli AK, Katta S, Fateh MV, et al. Design, optimization, and characterization of Zolmitriptan loaded liposomal gels for intranasal delivery for acute migraine therapy. Intell Pharm. 2025;3(1):11\u201325.","journal-title":"Intell Pharm."},{"key":"229_CR51","doi-asserted-by":"crossref","unstructured":"Aljabali AA, Obeid MA, Amawi HA, et al. Application of nanomaterials in the diagnosis and treatment of genetic disorders. In: Applications of nanomaterials in human health. Singapore: Springer Singapore; 2020:125\u2013146.","DOI":"10.1007\/978-981-15-4802-4_7"},{"key":"229_CR52","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/978-1-0716-1205-7_42","volume-title":"Melanoma","author":"MA Obeid","year":"2021","unstructured":"Obeid MA, Alyamani H, Amawi H, et al. siRNA delivery to melanoma cells with cationic niosomes. In: Hargadon KM, editor. Melanoma. New York, NY: Springer US; 2021:621\u2013634."},{"key":"229_CR53","doi-asserted-by":"crossref","unstructured":"Khunt D, Shah B, Lakhatariya M, et al. Lipid nanocrystals: an overview on formulation to clinical translation. In: Lipid-based drug delivery systems. New York: Jenny Stanford Publishing; 2023:125\u2013146.","DOI":"10.1201\/9781003459811-5"},{"issue":"8","key":"229_CR54","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/pharmaceutics15082065","volume":"15","author":"K Mo","year":"2023","unstructured":"Mo K, Kim A, Choe S, et al. Overview of solid lipid nanoparticles in breast cancer therapy. Pharmaceutics. 2023;15(8):2065.","journal-title":"Pharmaceutics."},{"key":"229_CR55","first-page":"016","volume":"2025","author":"HS Dhande","year":"2025","unstructured":"Dhande HS, Taksande JB, Awandekar NB, et al. Pharmacodynamic and physicochemical evaluation of intranasal zolmitriptan-loaded nanostructured lipid carriers: for enhanced antimigraine potential. ASSAY Drug Dev Technol. 2025:adt.2025.016.","journal-title":"ASSAY Drug Dev Technol."},{"issue":"5","key":"229_CR56","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1039\/D4PM00057A","volume":"1","author":"M Das","year":"2024","unstructured":"Das M, Sarma A, Baruah H, et al. Insight into central nervous system targeted nanostructured lipid carriers via the nose to brain pathway. RSC Pharm. 2024;1(5):904\u2013927.","journal-title":"RSC Pharm."},{"issue":"1","key":"229_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4155\/tde-2018-0051","volume":"10","author":"H Alyamani","year":"2019","unstructured":"Alyamani H, Obeid MA, Tate RJ, et al. Exosomes: fighting cancer with cancer. Ther Deliv. 2019;10(1):37\u201361.","journal-title":"Ther Deliv."},{"key":"229_CR58","volume":"5","author":"MA Obeid","year":"2023","unstructured":"Obeid MA, Haifawi S, Khadra I. The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing. Int J Pharm X. 2023;5:100168.","journal-title":"Int J Pharm X."},{"key":"229_CR59","doi-asserted-by":"crossref","unstructured":"Modi C, Kanada K, Prajapati B, et al. Transfersomes as Transporters via Lipid-Based Drug Delivery System. In: Lipid-based drug delivery systems. Singapore: Jenny Stanford Publishing; 2023:185\u2013212.","DOI":"10.1201\/9781003459811-7"},{"key":"229_CR60","doi-asserted-by":"crossref","unstructured":"Basu B, Dutta A, Parihar A, et al. Ethosomes: a lipid-based drug delivery system. In: Lipid-based drug delivery systems. Singapore: Jenny Stanford Publishing; 2023:223\u2013297.","DOI":"10.1201\/9781003459811-8"},{"issue":"5","key":"229_CR61","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/pharmaceutics17050583","volume":"17","author":"RM Almuqbil","year":"2025","unstructured":"Almuqbil RM, Aldhubiab B. Ethosome-based transdermal drug delivery: its structural components, preparation techniques, and therapeutic applications across metabolic, chronic, and oncological conditions. Pharmaceutics. 2025;17(5):583.","journal-title":"Pharmaceutics."},{"issue":"5","key":"229_CR62","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/chemistry6050058","volume":"6","author":"B Zhan","year":"2024","unstructured":"Zhan B, Wang J, Li H, et al. Ethosomes: a promising drug delivery platform for transdermal application. Chemistry. 2024;6(5):993\u20131019.","journal-title":"Chemistry."},{"issue":"22","key":"229_CR63","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.3390\/polym17223055","volume":"17","author":"C Ezzaki","year":"2025","unstructured":"Ezzaki C, Chaari A, Al-Othman A. Recent advances on chitosan-based nanoparticles for brain drug delivery. Polymers. 2025;17(22):3055.","journal-title":"Polymers."},{"issue":"6","key":"229_CR64","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/pharmaceutics16060746","volume":"16","author":"H Omidian","year":"2024","unstructured":"Omidian H, Gill EJ, Dey Chowdhury S, et al. Chitosan nanoparticles for intranasal drug delivery. Pharmaceutics. 2024;16(6):746.","journal-title":"Pharmaceutics."},{"issue":"3","key":"229_CR65","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.26452\/ijrps.v12i3.4786","volume":"12","author":"AJ Shinde","year":"2021","unstructured":"Shinde AJ, Swami KB, Tamboli FA, et al. Design and development of zolmitriptan niosomal in situ nasal gel for the treatment of migrain. Int J Res Pharm Sci. 2021;12(3):1861\u20131869.","journal-title":"Int J Res Pharm Sci."},{"issue":"7","key":"229_CR66","first-page":"122","volume":"14","author":"FF Mehta","year":"2025","unstructured":"Mehta FF, Patel J, Barot S, et al. Development and evaluation of in-situ nasal gel formulations of nanosized transferosomal triptans. J Neon Surg. 2025;14(7):122\u2013130.","journal-title":"J Neon Surg"},{"issue":"10","key":"229_CR67","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/jphp.13316","volume":"72","author":"M Masjedi","year":"2020","unstructured":"Masjedi M, Azadi A, Heidari R, et al. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. J Pharm Pharmacol. 2020;72(10):1341\u20131351.","journal-title":"J Pharm Pharmacol."},{"key":"229_CR68","unstructured":"Castelino C, Arnold K. Chitosan nanoparticle intranasal delivery of sumatriptan succinate. 2024;6(1)."},{"issue":"4","key":"229_CR69","first-page":"863","volume":"84","author":"AA Kempwade","year":"2022","unstructured":"Kempwade AA, Taranalli AD, Hiremath RD, et al. Formulation and evaluation of flexible liposome embedded in situ thermoreversible intranasal gel of rizatriptan benzoate. Indian J Pharm Sci. 2022;84(4):863\u2013873.","journal-title":"Indian J Pharm Sci."},{"issue":"5","key":"229_CR70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/adt.2022.044","volume":"20","author":"D Mathure","year":"2022","unstructured":"Mathure D, Ranpise H, Awasthi R, et al. Formulation and characterization of nanostructured lipid carriers of rizatriptan benzoate-Loaded In Situ Nasal gel for brain targeting. ASSAY Drug Dev Technol. 2022;20(5):211\u2013224.","journal-title":"ASSAY Drug Dev Technol."},{"key":"229_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/NSA.S442951","volume":"17","author":"M Hamzah","year":"2024","unstructured":"Hamzah M, Kassab H. Formulation and characterization of intranasal drug delivery of frovatriptan-loaded binary ethosomes gel for brain targeting. Nanotechnol Sci Appl. 2024;17:1\u201319.","journal-title":"Nanotechnol Sci Appl."},{"key":"229_CR72","doi-asserted-by":"crossref","unstructured":"Whealy M, Becker WJ. The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans. In: Migraine management. Amsterdam: Elsevier; 2024:17\u201342.","DOI":"10.1016\/B978-0-12-823357-3.00008-2"},{"key":"229_CR73","first-page":"203","volume":"199","author":"DD Mitsikostas","year":"2024","unstructured":"Mitsikostas DD, Ward TN. Evidence-based symptomatic treatment of migraine. Migraine Management. Amsterdam: Elsevier; 2024,199:203\u2013218.","journal-title":"Amsterdam: Elsevier"},{"key":"229_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/B978-0-12-823357-3.00017-3","volume":"199","author":"S Kamourieh","year":"2024","unstructured":"Kamourieh S, Rozen T, Anderson JMJHoCN. Status migrainosus. 2024;199:413\u2013439.","journal-title":"Handbook Clin Neurol"},{"key":"229_CR75","doi-asserted-by":"crossref","unstructured":"Abu-Arafeh I,\u00a0Howells R. Management of migraine in children and adolescents. Migraine Management. Amsterdam: Elsevier; 2024:487\u2013502.","DOI":"10.1016\/B978-0-12-823357-3.00034-3"},{"issue":"1","key":"229_CR76","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ijpharm.2018.07.014","volume":"548","author":"NAHA Youssef","year":"2018","unstructured":"Youssef NAHA, Kassem AA, Farid RM, et al. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. Int J Pharm. 2018;548(1):609\u2013624.","journal-title":"Int J Pharm."},{"key":"229_CR77","doi-asserted-by":"crossref","unstructured":"Rocha B, Rocha NP, Gago B. Translational challenges. In: Nanoparticles for brain drug delivery. Singapore: Jenny Stanford Publishing; 2021:453\u2013471.","DOI":"10.1201\/9781003119326-18"},{"key":"229_CR78","doi-asserted-by":"publisher","first-page":"1479993","DOI":"10.3389\/fnano.2024.1479993","volume":"6","author":"RV Kumarasamy","year":"2024","unstructured":"Kumarasamy RV, Natarajan PM, Umapathy VR, et al. Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. Front Nanotechnol. 2024;6:1479993.","journal-title":"Front Nanotechnol."},{"issue":"6","key":"229_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1208\/s12249-022-02330-9","volume":"23","author":"L Cai","year":"2022","unstructured":"Cai L, Xu H, Cui Z. Factors limiting the translatability of rodent model\u2013based intranasal vaccine research to humans. AAPS PharmSciTech. 2022;23(6):191.","journal-title":"AAPS PharmSciTech."},{"key":"229_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105648","volume":"150","author":"AO Stucki","year":"2024","unstructured":"Stucki AO, Sauer UG, Allen DG, et al. Differences in the anatomy and physiology of the human and rat respiratory tracts and impact on toxicological assessments. Regul Toxicol Pharmacol. 2024;150:105648.","journal-title":"Regul Toxicol Pharmacol."},{"issue":"6","key":"229_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/ctd2.253","volume":"3","author":"S Zheng","year":"2023","unstructured":"Zheng S, Guo Y, Yan F, et al. Chances and challenges in intranasal administration delivery for brain disease treatment. Clin Transl Discov. 2023;3(6):e253.","journal-title":"Clin Transl Discov."},{"issue":"3","key":"229_CR82","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/0333102420966984","volume":"41","author":"A Levine","year":"2021","unstructured":"Levine A, Vanderah TW, Largent-Milnes TM. An underrepresented majority: a systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine. Cephalalgia. 2021;41(3):404\u2013416.","journal-title":"Cephalalgia."},{"issue":"4","key":"229_CR83","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/brainsci14040317","volume":"14","author":"E Spekker","year":"2024","unstructured":"Spekker E, Fejes-Szab\u00f3 A, Nagy-Gr\u00f3cz G. Models of trigeminal activation: is there an animal model of migraine? Brain Sci. 2024;14(4):317.","journal-title":"Brain Sci."},{"issue":"1","key":"229_CR84","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/pharmaceutics16010058","volume":"16","author":"S Dighe","year":"2024","unstructured":"Dighe S, Jog S, Momin M, et al. Intranasal drug delivery by nanotechnology: advances in and challenges for Alzheimer\u2019s disease management. Pharmaceutics. 2024;16(1):58.","journal-title":"Pharmaceutics."},{"issue":"4","key":"229_CR85","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/pharmaceutics16040481","volume":"16","author":"S Gandhi","year":"2024","unstructured":"Gandhi S, Shastri DH, Shah J, et al. Nasal delivery to the brain: harnessing nanoparticles for effective drug transport. Pharmaceutics. 2024;16(4):481.","journal-title":"Pharmaceutics."},{"issue":"4","key":"229_CR86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/2211738510666220817120307","volume":"10","author":"AAA Aljabali","year":"2022","unstructured":"Aljabali AAA, Rezigue M, Alsharedeh RH, et al. Protein-based drug delivery nanomedicine platforms: recent developments. Pharm Nanotechnol. 2022;10(4):257\u2013267.","journal-title":"Pharm Nanotechnol."},{"issue":"6","key":"229_CR87","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4155\/tde-2020-0034","volume":"11","author":"S Hejmady","year":"2020","unstructured":"Hejmady S, Singhvi G, Saha RN, et al. Regulatory aspects in process development and scale-up of nanopharmaceuticals. Ther Deliv. 2020;11(6):341\u2013343.","journal-title":"Ther Deliv."},{"key":"229_CR88","doi-asserted-by":"publisher","first-page":"1735885","DOI":"10.3389\/fbioe.2026.1735885","volume":"14","author":"F Stucchi","year":"2026","unstructured":"Stucchi F, Li M, Castellano G, et al. Regulatory framework for polymer-based nanotherapeutics in clinical translation. Front Bioeng Biotechnol. 2026;14:1735885.","journal-title":"Front Bioeng Biotechnol."},{"key":"229_CR89","doi-asserted-by":"crossref","unstructured":"Aljabali AAA, Tambuwala MM, Obeid MA. Microfluidic manufacturing of niosomes. In: Microfluidics in pharmaceutical sciences. Cham: Springer Nature Switzerland; 2024:77\u2013108.","DOI":"10.1007\/978-3-031-60717-2_4"},{"issue":"4","key":"229_CR90","first-page":"184","volume":"7","author":"MM Hasan","year":"2016","unstructured":"Hasan MM, Rahman MM, Kabir A, et al. Contemporary investigation on nasal spray drug delivery system. 2016;7(4):184\u2013200.","journal-title":"J Pharm Therap"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-026-00229-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-026-00229-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-026-00229-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:03:07Z","timestamp":1786690987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-026-00229-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":90,"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s11596-026-00229-1","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Human Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}